News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actelion Ltd. Board Nominees Deny Sale is Main Aim
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - A group of prospective Actelion board members denied speculation they planned to prepare Europe's biggest biotech for sale and said they wanted instead to overhaul it.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
Business
BioSpace
Editors’ Top 5 Biggest News Stories of the Year
December 22, 2025
·
10 min read
·
Annalee Armstrong
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
December 18, 2025
·
1 min read
·
BioSpace Insights
